β2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 529-533

  Talan, Mark I ^a   Ahmet, Ismayil ^a   Xiao, Riu Ping ^a,b   Lakatta, Edward G ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

2 adrenergic receptor gonists; Beta adrenergic receptors; Cardiac remodeling; Chronic heart failure

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOTEROL; METOPROLOL; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

APOPTOSIS; ASTHMA; BETA ADRENERGIC STIMULATION; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEREOISOMERISM; SURVIVAL RATE; TACHYPHYLAXIS; VASODILATATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; TRANSLATIONAL RESEARCH;

RATTUS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; APOPTOSIS; CARBAZOLES; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80052792976     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.09.019     Document Type: Review

References (63)

1. Lefkowitz R.J. The superfamily of heptahelical receptors. Nature Cell Biol 2000, 2:E133-E136.
2. Giembycz M.A., Newton R. Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Eur Respir J 2006, 27:1286-1306. Review.
3. Giembycz M.A., Kaur M., Leigh R., Newton R. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008, 153:1090-1104. Review.
4. Lynch G.S., Ryall J.G. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 2008, 88:729-767. Review.
5. Hon J.K., Yacoub M.H. Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 2003, 75(Suppl):S36-S41.
6. Soppa G.K., Lee J., Stagg M.A., Felkin L.E., Barton P.J., Siedlecka U., et al. Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 2008, 77:695-706.
7. Prather I.D., Brown D.E., North P., Wilson J.R. Clenbuterol: a substitute for anabolic steroids?. Med Sci Sports Exerc 1995, 27:1118-1121.
8. Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 2000, 102. IV-14-IV- 23.
9. Chatterjee K., Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail 2007, 13:569-576. Review.
10. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982, 307:205-211.
11. Engelhardt S., Bohm M., Erdmann E., Lohse M.J. Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure. J Am Coll Cardiol 1996, 27:146-154.
12. Feldman D.S., Elton T.S., Sun B., Martin M.M., Ziolo M.T. Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiolvasc Med 2008, 5:208-218.
13. El-Armouche A., Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev 2009, 14:225-241. Review.
14. Faulx M.D., Ernsberger P., Vatner D., Hoffman R.D., Lewis W., Strachan R., et al. Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. Am J Physiol Heart Circ Physiol 2005, 289:H30-H36.
15. Liggett S.B., Cresci S., Kelly R.J., Syed F.M., Matkovich S.J., Hahn H.S., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008, 14:510-517.
16. O'Connor C.M., Gattis W.A., Uretsky B.F., Adams K.F., McNulty S.E., Grossman S.H., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999, 138:78-86.
17. Feldman A.M., Bristow M.R., Parmley W.W., Carson P.E., Pepine C.J., Gilbert E.M., et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993, 329:149-155.
18. Stevenson L.W. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation 2003, 108:492-497.
19. Brodde O.E., Zerkowski H.R., Borst H.G., Maier W., Michel M.C. Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. Eur Heart J 1989, 10:38-44. Suppl B.
20. Irmer M., Wollschläger H., Just H. Treatment of severe congestive heart failure with the beta-agonist fenoterol. Klin Wochenschr 1981, 59:639-645.
21. Mügge A., Posselt D., Reimer U., Schmitz W., Scholz H. Effects of the beta 2-adrenoceptor agonists fenoterol and salbutamol on force of contraction in isolated human ventricular myocardium. Klin Wochenschr 1985, 63:26-31.
22. Hall S.A., Cigarroa C.G., Marcoux L., Risser R.C., Grayburn P.A., Eichhorn E.J. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995, 25:1154-1161.
23. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
24. Lowes B.D., Gilbert E.M., Abraham W.T., Minobe W.A., Larrabee P., Ferguson D., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002, 346:1357-1365.
25. Satwani S., Dec G.W., Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004, 9:243-255.
26. Mudd J.O., Kass D.A. Reversing chronic remodeling in heart failure. Expert Rev Cardiovasc Ther 2007, 5:585-598.
27. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001, 110(Suppl 7A):81S-94S.
28. Howard P.A., Cheng J.W., Crouch M.A., Colucci V.J., Kalus J.S., Spinler S.A., et al. Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure. Ann Pharmacother 2006, 40:1607-1617. Review.
29. Narula J., Haider N., Virmani R., DiSalvo T.G., Kolodgie F.D., Hajjar R.J., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996, 335:1182-1189.
30. Olivetti G., Abbi R., Quaini F., Kajstura J., Cheng W., Nitahara J.A., et al. Apoptosis in the failing human heart. N Engl J Med 1997, 336:1131-1141.
31. Kostin S., Pool L., Elsässer A., Hein S., Drexler H.C., Arnon E., et al. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 2003, 92:715-724.
32. Xiao R.P., Ji X., Lakatta E.G. Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol 1995, 47:322-329.
33. Xiao R.P., Avdonin P., Zhou Y.Y., Cheng H., Akhter S.A., Eschenhagen T., et al. Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ. Res 1999, 84:43-52.
34. Xiao R.P., Zhang S.J., Chakir K., Avdonin P., Zhu W., Bond R.A., et al. Enhanced Gi signaling mediates the diminution of β2-adrenergic contractile response in failing spontaneous hypertensive rat heart. Circulation 2003, 108:1633-1639.
35. Chesley A., Ohtani S., Asai T., Xiao R.P., Lunberg M.S., Lakatta E.G., et al. β2-adrenergic receptor delivers an anti-apoptotic signal to cardiac myocytes through Gi-dependent signaling pathways. Circ Res 2000, 87:1172-1179.
36. Zhu W.Z., Zheng M., Lefkowitz R.J., Koch W.J., Kobilka B., Xiao R.P. Dual modulation of cardiac cell survival and cell death by β2-adrenergic signaling in adult mouse heart cells. Proc Nat Acad Sci USA 2001, 98:1607-1612.
37. Zhu W.Z., Wang S.Q., Chakir K., Kolbilka B.K., Cheng H., Xiao R.P. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/Calmodulin Kinase II. J. Clin. Invest 2003, 111:617-625.
38. Zheng M., Zhu W., Han Q., Xiao R.P. Emerging concepts and therapeutic implications of β-adrenergic receptor subtype signaling. Pharmacol Ther 2005, 509:109-115.
39. Zhu W., Woo A.Y., Yang D., Cheng H., Crow M.T., Xiao R.P. Activation of CaMKIIδc is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem 2007, 282:10833-10839.
40. Ahmet I., Krawczyk M., Heller P., Moon C., Lakatta E.G., Talan M.I. Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation 2004, 110:1083-1090.
41. Kast A., Tsunenari Y., Honma M., Nishikawa J., Shibata T., Torii M. Acute, subacute and chronic toxicity studies of the beta-sympathomimetic fenoterol HBr on rats, mice, and rabbits. Pharmacometrics 1975, 10:45-64.
42. Pearce N., Crane J., Burgess C., Beasley R., Jackson R. Fenoterol and asthma mortality. Lancet 1989, 1:1196-1197.
43. Lindmark B., Ottosson A. Beta2 agonists and heart failure. Lancet 1998, 352:1709-1710.
44. Martin R.M., Dunn N.R., Freemantle S.N., Mann R.D. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998, 53:558-562.
45. Jeppsson A.B., Waldeck B., Widmark E. Further studies on the cardiomegaly induced by β-adrenoceptor agonists. Acta Pharmacol Toxicol 1986, 58:121-125.
46. Leone M., Albanese J., Martin C. Positive inotropic stimulation. Curr Opin Crit Care 2002, 8:395-403.
47. Ryall J.G., Gregorevic P., Plant D.R., Sillence M.N., Lynch G.S. β2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am J Physiol Regul Integr Comp Physiol 2002, 283:R1386-R1394.
48. Sleeper M.M., Kearns C.F., McKeever K.H. Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exercise 2002, 34:643-650.
49. Ryall J.G., Plant D.R., Gregorevic P., Sillence M.N., Lynch G.S. β2-Agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 2004, 555:175-188.
50. Gregorevic P., Ryall J.G., Plant D.R., Sillence M.N., Lynch G.S. Chronic β-agonist administration affects cardiac function of adult but not old rats, independent of β-adrenoceptor density. Am J Physiol Heart Circ Physiol 2005, 289:H344-H349.
51. Speizer F.E., Doll R., Heaf P. Observations on recent increase in mortality from asthma. BMJ 1968, 1:335-339.
52. Abramson M.J., Walters J., Walters E.H. Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med 2003, 2:287-297. Review.
53. Corrao G., Zambon A., Faini S., Bagnardi V., Leoni O., Suissa S. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol 2005, 58:92-97.
54. Kast A., Tsunenari Y., Honma M., Iida H. Cardiac effects of fenoterol hydrobromide on newborn versus adult rats. Arzneimittelforschung 1985, 35:188-192.
55. Hancox R.J. Concluding remarks: can we explain the association of beta-agonists with asthma mortality? A hypothesis. Clin Rev Allergy Immunol 2006, 31:279-288.
56. Ahmet I., Lakatta E.G., Talan M.I. Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 2005, 10:289-296.
57. Li W.M., Gan R.T., Wang X., Wu S., Shen J.X., Xiu C.H. The effects of combined beta(1) adrenergic receptor antagonist and beta(2) adrenergic receptor agonist therapy on cardiac function and myocardial apoptosis in heart failure rats. Zhonghua Xin Xue Guan Bing Za Zhi 2007, 35:615-619. Chinese.
58. Ahmet I., Krawczyk M., Zhu W., Woo A.Y., Morrell C., Poosala S., et al. Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. J Pharmacol Exp Ther 2008, 325:491-499.
59. Ahmet I., Morrell C., Lakatta E.G., Talan M.I. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 2009, 331:178-185.
60. Molenaar P., Christ T., Ravens U., Kaumann A. Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. Cardiovasc Res 2006, 69:128-139.
61. Jozwiak K., Khalid C., Tanga M.J., Berzetei-Gurske I., Jimenez L., Kozocas J.A., et al. Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem 2007, 50:2903-2915.
62. Beigi F., Bertucci C., Zhu W., Chakir K., Wainer I.W., Xiao R.P., et al. Enantioselective separation and online affinity chromatographic characterization of R, R- and S, S-fenoterol. Chirality 2006, 18:822-827.
63. Woo A.Y., Wang T.B., Zeng X., Zhu W., Abernethy D.R., Wainer I.W., et al. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol 2009, 75:158-165.